|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's Range||19.55 - 20.78|
|52 Week Range||12.81 - 31.92|
|Beta (3Y Monthly)||1.08|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 4, 2017 - May 8, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.29|
WALTHAM, Mass., May 10, 2019 -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Pepe Carmona, Chief Financial Officer and Joe Kelly, Senior Vice President of Sales and.
Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing […]
Radius Health (RDUS) delivered earnings and revenue surprises of 1.05% and -14.22%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
TYMLOS® U.S. net sales were $29.8 million in the first quarter of 2019 doubling over the first quarter of 2018. TYMLOS continued increasing its share in the U.S. anabolic.
The Waltham, Massachusetts-based company said it had a loss of 94 cents per share. The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ...
Radius Health Inc NASDAQ NMS:RDUSView full report here! Summary * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is moderate for RDUS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $2.89 billion over the last one-month into ETFs that hold RDUS are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be remiss not to mention that insider sales have been known to precede tough periods for a business. So shareholders migh...
WALTHAM, Mass., April 23, 2019 -- Radius Health (Nasdaq: RDUS) announced today that it will release its first quarter 2019 financial results on Wednesday, May 8, 2019. The.
Radius Health, Inc. (RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced it will present two e-posters at the American Association of Clinical Endocrinologists 28th Annual Scientific & Clinical Conference in Los Angeles, CA. Radius Health will present two digital e-posters: data from a community-based study evaluating the association of type 2 diabetes (T2D) with fracture incidence over short- and long-term risk of fracture in both women and men and a post-hoc analysis evaluating the efficacy of abaloparatide followed by alendronate vs. placebo followed by alendronate in a subset of women from the Phase 3 ACTIVE trial with T2D.
Radius Health's (RDUS) lead drug, Tymlos, gains traction in 2018. Let us see how the drug will fare in 2019 amid increasing competition.
Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEW YORK, March 29, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
Radius Health, Inc. (RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today presented a post-hoc analysis of Phase 3 data from different patient populations included in the ACTIVE trial, and results from preclinical studies of abaloparatide and its effect on the development and growth of osteoclasts and on bone resorption during an oral session at ENDO 2019, the Endocrine Society’s Annual Meeting and Expo in New Orleans, LA. The first oral presentation titled “The Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis,” showed that in a subpopulation of postmenopausal women from the ACTIVE study who also had osteoarthritis (OA), abaloparatide was associated with significant reduction in new vertebral fractures as well as significant improvements in bone mineral density (BMD), versus placebo.
Radius Health, Inc. (RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced it will present data on TYMLOS® (abaloparatide) injection at ENDO 2019, the Endocrine Society’s Annual Meeting and Expo in New Orleans, LA. During an oral session, Radius Health will present two abstracts on abaloparatide injection: a post-hoc analysis in a subset of women from the Phase 3 ACTIVE trial who have both postmenopausal osteoporosis (PMO) and osteoarthritis, and data from preclinical studies that provide mechanistic explanations for the net bone gain observed in ACTIVE in abaloparatide-treated patients.
WALTHAM, Mass., March 11, 2019 -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President and CEO of the Company, will present a corporate update at.
While not a mind-blowing move, it is good to see that the Radius Health, Inc. (NASDAQ:RDUS) share price has gained 15% in the last three months. But in truth theRead More...